Rapid Antibody Testing for COVID-19

Covi-G (powered by Cipla) Rapid Test kit combines quality, efficacy and convenience - offering precise results in 10-15 mins Features & Benefits Covid IgM-IgG Serologic Rapid Test for COVID-19 is used to qualitatively detect IgG and IgM antibodies against SARS-CoV-2 in whole blood in vitro Precise and effective - Tests for both IgM and IgG antibodies - Sensitivity and specificity comparable to highest available offerings Sensitivity: IgG 92%, IgM 82%; Specificity IgG 97%, IgM 94% - ->92% total accuracy: IgG 96,5% - IgM: 92,8% - High reproducibility (consistent results across the same patient) - High quality, reliable & convenient - Single-prick blood test - 10-15 minutes per test - Intuitive visual interpretation - No specialized training or equipment needed - Portable hence highly scalable - Storage at room temperature (2-30 C) - Conformance to CE (Europe) and ISO manufacturing The Covi-G platform for Rapid Antibody tests has a set of unique and unparalleled offerings SUSTAINABLE QUALITY Validated Declaration of CE conformity - Launched in Feb 2020, among the earliest technologies/ kits to declare CE-compliance, and continuing strong compared to competitors - Under process for receiving USDA E authorization Among only 3 integrated vendors of Rapid tests Developed and manufactured in Europe (Belgium) - One of the very lew players manufacturing in Europe, with zero complaints also certified locations ACCEPTABILITY ACROSS MARKETS Demonstrated capabilities in local countries validation - Independent local studies conducted in Belgium and France, validating the sensitivity and specificity of the product Participated in published research - Covl-G kit compared lavorably with 7 lgFL IgM rapid antibody tests and IgG ELISA in a comparative study published by Elsevier Science Direct, verifying sensitivity of the kit PROVEN COMMERCIAL EXPERIENCE Sold in 25+ countries already - Including Europe, US, Canada, Africa and multiple developed and emerging markets - Under participation in govt tenders Robust manufacturing capability and capacity - ISO-certified manufacturing site - Ability to cater to high manufacturing volumes from Belgium, to ensure adequale QA and commercial viability AFFORDABLE AND SCALABLE Viable to scale up at Institutions and Retail level - Economical cost per-unit established over many months of process improvement and local manufacturing - Can cater to insured as well as out-of pocket populations Continuous improvement through R&D - Multiple rounds of performance testing complete, further testing in 5 reputed hospitals underway in Belgium, France, USA and Canada - Other platforms including Rapid antigen testing also being developed The price is per unit, the minimum is 25000 units